Literature DB >> 7949124

Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.

T E Warkentin1, C P Hayward, L K Boshkov, A V Santos, J A Sheppard, A P Bode, J G Kelton.   

Abstract

Heparin-induced thrombocytopenia is characterized by moderate thrombocytopenia and thrombotic complications, whereas quinine/quinidine-induced thrombocytopenia usually presents with severe thrombocytopenia and bleeding. Using flow cytometry and assays of procoagulant activity, we investigated whether sera from patients with these immune drug reactions could stimulate normal platelets to generate platelet-derived microparticles with procoagulant activity. Sera or purified IgG from patients with heparin-induced thrombocytopenia stimulated the formation of platelet-derived microparticles in a heparin-dependent fashion. Further studies showed that heparin-induced thrombocytopenia sera also produced a marked increase in procoagulant activity. In contrast, sera from patients with quinine- or quinidine-induced thrombocytopenia did not generate platelet-derived microparticles nor generate increased procoagulant activity. However, quinine/quinidine-induced thrombocytopenia sera produced a significant increase in the binding of IgG to platelets in a drug-dependent fashion, whereas sera from patients with heparin-induced thrombocytopenia demonstrated no drug-dependent binding of IgG to platelets. We also observed increased levels of circulating microparticles in patients with acute heparin-induced thrombocytopenia compared with control patients. Our observations indicate that the generation of procoagulant platelet-derived microparticles in vivo is a plausible explanation for the thrombotic complications observed in some patients with heparin-induced thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949124

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  59 in total

Review 1.  Heparin-induced thrombocytopenia: patient profiles and clinical manifestations.

Authors:  F A Spencer
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

Review 2.  Laboratory testing for heparin-induced thrombocytopenia.

Authors:  T E Warkentin
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

Review 3.  Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.

Authors:  N Lubenow; A Greinacher
Journal:  J Thromb Thrombolysis       Date:  2000-11       Impact factor: 2.300

Review 4.  Function and clinical significance of platelet-derived microparticles.

Authors:  S Nomura
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

5.  Internalization of IgG-coated targets results in activation and secretion of soluble CD40 ligand and RANTES by human platelets.

Authors:  Adam J Antczak; Joshua A Vieth; Navinderjit Singh; Randall G Worth
Journal:  Clin Vaccine Immunol       Date:  2010-12-22

Review 6.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

7.  Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation.

Authors:  Jason M Aliotta; Fermin M Sanchez-Guijo; Gerri J Dooner; Kevin W Johnson; Mark S Dooner; Kenneth A Greer; Deborah Greer; Jeffrey Pimentel; Luiz M Kolankiewicz; Napoleon Puente; Sam Faradyan; Paulette Ferland; Elaine L Bearer; Michael A Passero; Mehrdad Adedi; Gerald A Colvin; Peter J Quesenberry
Journal:  Stem Cells       Date:  2007-06-07       Impact factor: 6.277

Review 8.  Heparin-induced thrombocytopenia and thrombosis.

Authors:  G Arepally; D B Cines
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 9.  Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.

Authors:  Daniela R Junqueira; Liliane M Zorzela; Edson Perini
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

10.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Gowthami M Arepally; Beng H Chong; Douglas B Cines; Andreas Greinacher; Yves Gruel; Lori A Linkins; Stephen B Rodner; Sixten Selleng; Theodore E Warkentin; Ashleigh Wex; Reem A Mustafa; Rebecca L Morgan; Nancy Santesso
Journal:  Blood Adv       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.